Study wrapper · #1190
Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity.
Editor's note
A large propensity-matched real-world comparison, and the direction holds across every subgroup and sensitivity analysis the authors ran. The caveats are the usual ones for retrospective cohorts: residual confounding, no randomisation, and semaglutide exposure inferred from refill records rather than measured. Read the results as comparative context for surgical versus pharmacologic paths in obesity care, not as evidence that semaglutide itself raises cardiovascular risk.
Plain-language abstract
Using a large US health-records network, researchers matched adults with obesity who started semaglutide against a similar number who underwent sleeve gastrectomy or gastric bypass, then followed both groups for up to five years. Major cardiovascular events - coronary events, strokes, heart failure and cardiac arrest - were roughly half as common after surgery as with semaglutide, whether or not the patient had type 2 diabetes. The difference was widest for heart failure.